Kalaris Therapeutics (KLRS) vs RenovoRx (RNXT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
RenovoRx (RNXT) has outperformed Kalaris Therapeutics (KLRS) over the past year, gaining 9.9% versus a loss of 62.1%. Over five years, RNXT leads with a -77.8% price change compared with -99.5% for KLRS. RenovoRx is the larger company by market cap ($60.0 million vs $59.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KLRS | RNXT |
|---|---|---|
| Share price | $2.50 | $1.33 |
| Market cap | $59.51M | $60.02M |
| 1-day change | -2.34% | -2.92% |
| YTD return | -70.38% | +58.33% |
| 1-year return | -62.06% | +9.92% |
| 5-year return | -99.51% | -77.76% |
| EPS (TTM) | $-2.02 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.88 | $2.59 |
| 52-week low | $2.35 | $0.701 |
| Distance from 52-week high | -78.96% | -48.65% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +648.40% | +436.09% |
| Average volume | 252.88K | 761.09K |
| Shares outstanding | 23.80M | 45.13M |
| Employees | 20 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNXT has outperformed KLRS by 72.0 percentage points over the past year.
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Healthcare · Biotechnology · 20 employees
About RenovoRx
RNXT stock →RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
Healthcare · Biotechnology · 17 employees
KLRS vs RNXT FAQ
Which is bigger, Kalaris Therapeutics or RenovoRx?
RenovoRx (RNXT) is larger, with a market capitalization of $60.02M compared with $59.51M for Kalaris Therapeutics (KLRS).
Which stock has performed better over the past year, KLRS or RNXT?
RNXT returned +9.92% over the past 12 months, compared with -62.06% for KLRS (price return, excluding dividends). Past performance does not predict future results.
Are Kalaris Therapeutics and RenovoRx in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.